December 28, 2004
The Hospital of the University
Enrolling Patients in Clinical Trial for Treating
Idiopathic Pulmonary Fibrosis
(Philadelphia, PA) – The Hospital of
the University of Pennsylvania (HUP) is seeking
participants in an international, Phase 3 clinical trial,
called the INSPIRE Trial. This randomized, double-blind,
placebo-controlled research study will evaluate the
therapeutic potential of interferon gamma-1b –
a manufactured version of a naturally occurring human
protein that stimulates the immune system – in
the treatment of Idiopathic Pulmonary Fibrosis (IPF).
IPF is a debilitating and potentially deadly lung disease
affecting more than 80,000 people in the United States.
HUP is one of 75 leading medical centers in North America
and Europe participating in the INSPIRE Trial.
IPF is a disease characterized by progressive scarring
(fibrosis) of the lungs. Symptoms include a progressively
worsening shortness of breath (dyspnea), which makes
it difficult to perform routine tasks, such as walking.
Ultimately the loss of lung function leads to death.
The cause of IPF is unknown, and currently there is
no FDA-approved treatment for this fatal disease.
Investigators hope to enroll 12 participants in the
Delaware Valley and a total of 600 patients around the
world will be enrolled. Adults with IPF may be eligible
to participate in the INSPIRE Trial if they are between
the ages of 40 and 79, have been diagnosed within the
past 36 months, and meet trial eligibility requirements.
Those enrolled will receive either the investigational
study drug or placebo by subcutaneous injection three
times a week for a minimum of two years. For more information
on the trial and eligibility, contact the study’s
research coordinator, Susan Metzger, MSN, RN, at 215.662.3115
or via e-mail at email@example.com.
You can also visit the trial’s web site at www.inspiretrial.com
for more information.
a printer friendly version of this release,
PENN Medicine is a $2.7 billion
enterprise dedicated to the related missions of medical
education, biomedical research, and high-quality patient
care. PENN Medicine consists of the University of Pennsylvania
School of Medicine (founded in 1765 as the nation’s
first medical school) and the University of Pennsylvania
Health System (created in 1993 as the nation’s
first integrated academic health system).
Penn’s School of Medicine is ranked #3 in the
nation for receipt of NIH research funds; and ranked
#4 in the nation in U.S. News & World Report’s
most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its
superior education and training of the next generation
of physician-scientists and leaders of academic medicine.
Penn Health System is comprised of: its flagship hospital,
the Hospital of the University of Pennsylvania, consistently
rated one of the nation’s “Honor Roll”
hospitals by U.S. News & World Report; Pennsylvania
Hospital, the nation's first hospital; Presbyterian
Medical Center; a faculty practice plan; a primary-care
provider network; two multispecialty satellite facilities;
and home health care and hospice.